

Lifeline Scientific, Inc.
("Lifeline" or "the Company")

Exercise of options and TVR

Itasca, Illinois, US, 14 May 2010 - Lifeline Scientific, the medical technology company focused on the worldwide commercialisation of its LifePort® Kidney Transporter, a product designed to address the global challenge of human donor organ shortages, announces that on the 7 of May 2010 an employee exercised 2,500 of their vested options.

Application has been made for the admission of the 2,500 common shares (Reg S) to trading on the AIM market. Admission is expected to occur on 20 May 2010.

Following today's application, Lifeline has 17,511,864 common shares in issue and each share has the right to one vote. Therefore for the purposes of the FSA Disclosure and Transparency Rules the total number of voting rights in the Company is 17,511,864.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify the Company of their interests in, or change to their interests in, Lifeline Scientific, Inc. under the FSA's Disclosure and Transparency Rules.

Following today's application, 7,351,909 common shares remain subject to Regulation S restrictions and are held in certificated form only. These common shares subject to Regulation S restrictions are traded under ISIN number USU529641008.

The remaining 10,159,955 common shares have had the Regulation S restrictions lifted and are held in uncertificated form trading under ISIN number US53223V1017.

Enquiries:

Lifeline Scientific, Inc.	+ 1 847 294 0300
David Kravitz, CEO	
Seymour Pierce (Nominated Adviser and Broker)	+44 (0)20 7107 8000
Mark Percy (Corporate Finance)	
David Banks (Corporate Broking)	
Financial Dynamics	+44 (0)20 7831 3113
Ben Brewerton / John Dineen	

About the LifePort Kidney Transporter

Created with the challenges of organ recovery and transport in mind, LifePort Kidney Transporter is designed to provide improved kidney preservation, evaluation and transport prior to transplantation. LifePort provides a sealed, sterile, protected environment where a solution is gently pumped through the kidney at cold temperatures to minimize damage while the organ is outside the body. LifePort is lightweight and portable, allowing organs to be perfused from the time of recovery until transplant. It is designed to travel unaccompanied by land or air, safely

transporting the kidneys across town or between countries. While the kidney is being perfused, the LifePort records data on temperature, flow rate vascular resistance and pressure every 10 seconds providing surgeons with additional data prior to transplant.

About Lifeline Scientific Inc.

Lifeline Scientific, Inc. is a Chicago-based global medical technology company with European headquarters located in Brussels. Its primary focus is to commercialise its FDA approved, CE marked, clinically validated and revenue generating LifePort Kidney Transporter. Devices for preservation of the heart, lung pancreas and liver are in late stage pre-clinical development.

For further information please see www.lifeline-scientific.com